NEIGHBOURS CALLING:      Dubai      Malaysia     Nepal     Bhutan
  HOME       Contact Us      Hire Us       Domestic Airlines        Railway Enquiry     Railway Booking     Hotels Abroad
indiatraveltimes.com
CORONAVIRUS CASUALTIES (Aug 4):- GLOBAL:- Total Cases: 1,84,80,862; Total Deaths: 6,98,257 Recovered: 1,17,06,691 BELGIUM:- Total Cases: 70,314; Total Deaths: 9,850 BRAZIL:- Total Cases: 27,51,665; Total deaths: 94,702 CANADA:- Total Cases: 1,17,031; Total Deaths: 8,947 CHINA:- Total Cases: 84,464 ; Total Deaths: 4,635 FRANCE:- Total Cases: 1,91,295; Total Deaths: 30,294 GERMANY:- Total Cases: 2,12,331; Total Deaths: 9,232 INDIA:- Total Cases: 18,64,561; Total Deaths: 39,057 INDONESIA:- Total Cases: 1,15,056; Total Deaths: 5,388 IRAN:- Total Cases: 3,14,786; Total Deaths: 17,617 ITALY:- Total Cases: 2,48,229; Total Deaths: 35,166 JAPAN:- Total Cases: 38,687 ; Total Deaths: 1012 MEXICO:- Total Cases: 4,43,813; Total Deaths: 48,012 NETHERLANDS:- Total Cases: 55,470; Total Deaths: 6,149 PHILIPPINES:- Total Cases: 1,12,593; Total Deaths: 2,115 RUSSIA:- Total Cases: 8,61,423; Total Deaths: 14,351 S KOREA:- Total Cases: 14,423; Total Deaths: 301 SPAIN:-Total Cases: 3,44,134; Total Deaths: 28,472 SWEDEN:- Total Cases: 81,012; Total Deaths: 5,744 SWITZERLAND:-Total Cases: 35,746; Total Deaths: 1,981 UAE:- Total Cases: 61,352; Total Deaths:351 UK:- Total Cases: 3,05,623; Total Deaths: 46,210 US:- Total Cases: 48,63,077; Total Deaths: 1,58,975 - India Travel Times.Com   [Estd: 1998]       * * *    Travel, More Travel, Travel Means A Million Things     * * *    

Cipla's Favipiravir branded as Ciplenza priced at Rs 68 per tablet to be available by Aug first week

Favipiravir has shown promising results in fighting covid in mild and moderate cases. Glenmark's reduced price of its Favipiravir branded as FabiFlu is Rs 75 per tablet and the treatment for 14 days costs Rs 10,200.

NEW DELHI, July 25: Cipla-produced anti-viral, re-purposed Favipiravir, brand-named as Ciplenza, was given regulatory nod by DCGI on Friday to sell the drug in the market. It will be available through hospital channels for use under emergency authorisation from the first week of August for Rs 68 per tablet.

Favipiravir is an anti-viral drug developed by Fuji Pharma of Japan. It is now re-purposed as a therapy for coronavirus. It shows promising results in fighting covid in mild and moderate cases. It is off-patented and Cipla is launching it in India.

It has been reported that CSIR-IICT developed a cost-effective process using locally available chemicals to synthesise the Active Pharmaceutical Ingredient (API) and transferred the technolgy to Cipla.

Meanwhile, Glenmark Pharma has reduced the price of its Favipiravir branded as FabiFlu by 27% to Rs 75 per tablet from Rs 103 after the DCGI wrote that the price was too high for the poor patients of coronavirus. The treatment cost of a 14-day regimen will come down to Rs 10,200 from Rs14,000. The pharma had received manufacturing and marketing approval from the DCGI last month after It had completed the phase 3 clinical trial in mild to moderate covid patients in India.

Glenmark is also trying a combination therapy using Umifenovir in moderate hospitalised cases.





Previous Files


Custom Search